The challenge is to get these results into clinical practice, to get the drug used by the people who will benefit from it, who will live longer without dialysis, without heart attacks, without strokes, if they take this drug. Novo Nordisk will need to seek regulatory approval for semaglutide to be used to treat those with chronic kidney disease
Manufacturer: Victoza and Saxenda (Novo Nordisk)
GLP-1 prescriptions for those aged 18 to 39 increased 588%, from 0.19% in 2019 to 1.33% in 2024
Sikiric P, Mikus D, Seiwerth S, et al
In the pancreas, semaglutide stimulates insulin secretion in a glucose-dependent manner, meaning it promotes insulin release only when blood glucose levels are elevated
Survodutide Bloodwork: 8 Labs to Track Liver enzymes are the one most skip and shouldn't with a glucagon agonist